Brief: Anteris Technologies Announces FY Loss Attributable Of A$67.3 Mln
Feb 28 (Reuters) - Anteris Technologies Ltd AVR.AX :
* FY LOSS ATTRIBUTABLE A$67.3 MILLION VERSUS LOSS A$44.3
MILLION
* GROUP IS AIMING TO SECURE APPROVAL FROM FDA TO UNDERTAKE A
PIVOTAL CLINICAL TRIAL
* FY REVENUE FROM ORDINARY ACTIVITIES A$4.1 MILLION VERSUS
A$4.6
MILLION
Source text for Eikon: ID:nASX4lgRdt
Further company coverage: AVR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anteris Technologies
See all newsBrief: Anteris Technologies Global Corp Gets French Regulatory Clearance For Duravr Paradigm Global Pivotal Trial
Anteris Technologies up as brokerages initiate coverage post-research quiet period
Brief: Anteris Technologies Says Aggregate Gross Proceeds From Offering Was $88.8 Mln
Anteris Technologies slides in Nasdaq debut after $89 mln US IPO
Brief: Anteris Technologies Prices 14.8 Mln Shares At $6.00 Per Share for U.S. IPO